Changes and clinical significance of CD8+CD122+ T cells in the peripheral blood of patients with ankylosing spondylitis
- 110 Downloads
The aim of our study was to explore the relationship between circulating T cells and ankylosing spondylitis (AS) and to find the role of the CD8+CD122+ T cells in the pathogenesis and progression of AS. With the method of case-control design, flow cytometry was performed to quantitatively determine the percentage of circulating CD8+CD122+ T cells in peripheral blood mononuclear cells from established AS patients and age- and gender-matched healthy controls. Serum levels of inflammatory cytokines like interleukin-2, interleukin-10, interleukin-15, TGF-β1, and TNF-ɑ were detected by enzyme-linked immunosorbent assay. The t test was used to compare differences between groups, correlation analysis with Spearman rank test and Pearson correlation was performed. The percentage of circulating CD8+CD122+ T cells were significantly increased in AS patients compared with controls (Z = − 4.917, P = 0.001). Plasma IL-2, IL-10, IL-15, TGF-β1, and TNF-ɑ levels between cases and controls were analyzed but no statistically significant differences were found. The percentage of circulating CD8+CD122+ T cells were not significantly different in the two groups of patients with AS whether they were treated or not. In addition, the percentage of circulating CD8+CD122+ T cells was positively correlated with disease duration, CRP, and ASDAS-CRP. The CD8+CD122+ T cells in the peripheral blood of AS patients may be involved in the development of AS, and they may coordinate regulate inflammation and immune dysregulation in patients with AS, which may play an important role in the pathogenesis and prognosis of AS.
KeywordsAnkylosing spondylitis CD8+CD122+ Cytokine Regulatory T cells
We thank all the patients and blood donors who participated in our study.
Compliance with ethical standards
The study was approved by the Local Ethics Research Committee of Anhui Medical University, and all patients and controls gave their written informed consent. The procedures followed the tenets of the Declaration of Helsinki.
- 3.Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landewé R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Wei J, Brachat A, Bek S, Laurent D, Li Y, Wang YA, Bertolino AP, Gsteiger S, Wright AM, Hueber W (2013) Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382(9906):1705–1713. https://doi.org/10.1016/s0140-6736(13)61134-4 CrossRefPubMedGoogle Scholar
- 4.Wu JJ, Penfold RB, Primatesta P, Fox TK, Stewart C, Reddy SP, Egeberg A, Liu J, Simon G (2017) The risk of depression, suicidal ideation, and suicide attempt in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis. J Eur Acad Dermatol Venereol. https://doi.org/10.1111/jdv.14175
- 7.Ji W, Li H, Gao F, Chen Y, Zhong L, Wang D (2014) Effects of tripterygium glycosides on interleukin-17 and CD4+CD25+CD127low regulatory T-cell expression in the peripheral blood of patients with ankylosing spondylitis. Biomed Rep 2(4):517–520. https://doi.org/10.3892/br.2014.262 CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Ciccia F, Accardo-Palumbo A, Giardina A, Di Maggio P, Principato A, Bombardieri M, Rizzo A, Alessandro R, Ferrante A, Principe S, Peralta S, Conte F, Drago S, Craxi A, De Leo G, Triolo G (2010) Expansion of intestinal CD4+CD25(high) Treg cells in patients with ankylosing spondylitis: a putative role for interleukin-10 in preventing intestinal Th17 response. Arthritis Rheum 62(12):3625–3634. https://doi.org/10.1002/art.27699 CrossRefPubMedGoogle Scholar
- 13.Tang J, Zhang X (2012) Changes and significance of CD8+CD122+ regulatory T cell and interleukin-10 in rheumatoid arthritis. Lab Med Clin 11:1331–1332Google Scholar
- 18.Szanto S, Aleksza M, Mihaly E, Lakos G, Szabo Z, Vegvari A, Sipka S, Szekanecz Z (2008) Intracytoplasmic cytokine expression and T cell subset distribution in the peripheral blood of patients with ankylosing spondylitis. J Rheumatol 35(12):2372–2375. https://doi.org/10.3899/jrheum.070839 CrossRefPubMedGoogle Scholar
- 25.Kavanaugh A, Tutuncu Z, Catalan-Sanchez T (2006) Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis. Curr Opin Rheumatol 18(4):347–353. https://doi.org/10.1097/01.bor.0000231901.19795.8a PubMedGoogle Scholar